Apeiron Therapeutics, strategically based in the San Francisco Bay Area and Shanghai, is a clinical-stage biopharmaceutical company developing biomarker-driven cancer therapeutics. Leveraging structure-based, AI-driven drug design and tapping into technologies and talent from global biotechnology hubs, we develop best-in-class and first-in-class small molecule therapies to improve patient outcomes. Integrating cutting-edge artificial intelligence with deep drug discovery expertise, Apeiron advances a robust pipeline of targeted cancer treatments addressing unmet medical needs.

To learn more about our team, R&D, or presentations please click on the respective links in the menu bar or contact us directly: info@apeiron-bio.com.